[HTML][HTML] Therapeutic targeting of the IGF axis
E Osher, VM Macaulay - Cells, 2019 - mdpi.com
The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and
development, and when deregulated makes an important contribution to disease. Here, we …
development, and when deregulated makes an important contribution to disease. Here, we …
[HTML][HTML] Growth hormone/insulin growth factor axis in sex steroid associated disorders and related cancers
R Bleach, M Sherlock, MW O'Reilly… - Frontiers in Cell and …, 2021 - frontiersin.org
To date, almost all solid malignancies have implicated insulin-like growth factor (IGF)
signalling as a driver of tumour growth. However, the remarkable level of crosstalk between …
signalling as a driver of tumour growth. However, the remarkable level of crosstalk between …
[HTML][HTML] Blockade of IGF/IGF-1R signaling axis with soluble IGF-1R mutants suppresses the cell proliferation and tumor growth of human osteosarcoma
D Cao, Y Lei, Z Ye, L Zhao, H Wang… - American journal of …, 2020 - ncbi.nlm.nih.gov
Primary bone tumor, also known as osteosarcoma (OS), is the most common primary
malignancy of bone in children and young adults. Current treatment protocols yield a 5-year …
malignancy of bone in children and young adults. Current treatment protocols yield a 5-year …
Nanomedicine for the treatment of advanced prostate cancer
S Vicente‐Ruiz, A Serrano‐Martí… - Advanced …, 2021 - Wiley Online Library
Current prostate cancer (PCa) treatment options include hormonal therapy, chemotherapy,
immunotherapy, and radiotherapy; however, a lack of targeting and overall efficiency has …
immunotherapy, and radiotherapy; however, a lack of targeting and overall efficiency has …
A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors
T Doi, Y Kuboki, Y Naito, M Ishida, T Tanaka… - Cancer …, 2022 - Wiley Online Library
Xentuzumab is an insulin‐like growth factor (IGF) ligand‐neutralizing antibody. This phase 1
trial assessed xentuzumab in Japanese patients with solid tumors. Patients aged≥ 20 y old …
trial assessed xentuzumab in Japanese patients with solid tumors. Patients aged≥ 20 y old …
[HTML][HTML] Important players in carcinogenesis as potential targets in cancer therapy: an update
JM Hermanowicz, I Kwiatkowska, D Pawlak - Oncotarget, 2020 - ncbi.nlm.nih.gov
The development of cancer is a problem that has accompanied mankind for years. The
growing number of cases, emerging drug resistance, and the need to reduce the serious …
growing number of cases, emerging drug resistance, and the need to reduce the serious …
A phase 1 trial of xentuzumab, an IGF-neutralizing antibody, in Japanese patients with advanced solid tumors.
Y Kuboki, Y Naito, M Ishida, T Tanaka, Y Takeuchi - Cancer …, 2022 - europepmc.org
Xentuzumab is an insulin‐like growth factor (IGF) ligand‐neutralizing antibody. This phase 1
trial assessed xentuzumab in Japanese patients with solid tumors. Patients aged≥ 20 y old …
trial assessed xentuzumab in Japanese patients with solid tumors. Patients aged≥ 20 y old …